Center for Drug Evaluation and Research

Approval Package for:

Application Number:

NDA 17-473/S046

Trade Name: Orap

Generic Name: pimozide

Sponsor: Teva Pharmaceuticals USA

Approval Date: September 27, 2011

Indications: for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment.
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review / Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td>X</td>
</tr>
<tr>
<td>Summary Review</td>
<td></td>
</tr>
<tr>
<td>Officer/Employee List</td>
<td></td>
</tr>
<tr>
<td>Office Director Memo</td>
<td></td>
</tr>
<tr>
<td>Cross Discipline Team Leader Review</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Environmental Assessment</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Risk Assessment and Risk Mitigation Review(s)</td>
<td></td>
</tr>
<tr>
<td>Proprietary Name Review(s)</td>
<td></td>
</tr>
<tr>
<td>Other Review(s)</td>
<td>X</td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
APPLICATION NUMBER:
NDA 17-473/S046

APPROVAL LETTER
Dear Mr. Ahern:

Please refer to your Supplemental New Drug Application (sNDA) dated and received September 15, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Orap (pimozide) 1 mg and 2 mg Tablets.

Reference is also made an Agency letter dated August 17, 2011, requesting revised labeling based upon our review of pharmacokinetic and safety information for pimozide as related to intrinsic defects in CYP2D6 metabolism.

This “Prior Approval” supplemental new drug application provides for revisions to the CLINICAL PHARMACOLOGY-Metabolism and Pharmacokinetics, CONTRAINDICATIONS, PRECAUTIONS-Drug Interactions, and DOSAGE AND ADMINISTRATION sections as well as the addition of a new subsection under PRECAUTIONS entitled Pharmacogenomics.

We note that you have incorporated our requested revisions, verbatim.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.
Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact CDR Kofi Ansah, Senior Regulatory Project Manager, at (301)796-4158 or email: Kofi.Ansah@fda.hhs.gov.

Sincerely,

 dessa electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
09/27/2011
APPLICATION NUMBER:
NDA 17-473/S046

LABELING
DESCRIPTION

ORAP® (pimozide) is an orally active antipsychotic agent of the diphenyl-butylpiperidine series. The structural formula of pimozide, 1-[1-[4,4-bis(4-fluorophenyl) butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one is:

The solubility of pimozide in water is less than 0.01 mg/mL; it is slightly soluble in most organic solvents.

Each white ORAP tablet contains either 1 mg or 2 mg of pimozide and the following inactive ingredients: calcium stearate, microcrystalline cellulose, lactose anhydrous and corn starch.

CLINICAL PHARMACOLOGY

Pharmacodynamic Actions

ORAP (pimozide) is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. Although its exact mode of action has not been established, the ability of pimozide to suppress motor and phonic tics in Tourette’s Disorder is thought to be a function of its dopaminergic blocking activity. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide’s therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized.

Metabolism and Pharmacokinetics

More than 50% of a dose of pimozide is absorbed after oral administration. Based on the pharmacokinetic and metabolic profile, pimozide appears to undergo significant first pass...
metabolism. Peak serum levels occur generally six to eight hours (range 4-12 hours) after dosing.

Pimozide is extensively metabolized, primarily by N-dealkylation in the liver. This metabolism is catalyzed mainly by the cytochrome P450 3A4 (CYP 3A4) enzymatic system and to a lesser extent, by cytochrome P450 1A2 (CYP 1A2) and cytochrome P450 2D6 (CYP 2D6). Two major metabolites have been identified, 1-(4-piperidyl)-2-benzimidazolinone and 4,4-bis(4-fluorophenyl) butyric acid. The antipsychotic activity of these metabolites is undetermined. The major route of elimination of pimozide and its metabolites is through the kidney.

The mean serum elimination half-life of pimozide in schizophrenic patients was approximately 55 hours. There was a 13-fold interindividual difference in the area under the serum pimozide level-time curve and an equivalent degree of variation in peak serum levels among patients studied. The significance of this is unclear since there are few correlations between plasma levels and clinical findings.

Effects of food and disease upon the absorption, distribution, metabolism and elimination of pimozide are not known. Effects of concomitant medication and genetic variations on pimozide metabolism are described in the CONTRAINDICATIONS and PRECAUTIONS sections.

INDICATIONS AND USAGE
ORAP (pimozide) is indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. ORAP is not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. ORAP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics.

Evidence supporting approval of pimozide for use in Tourette’s Disorder was obtained in two controlled clinical investigations which enrolled patients between the ages of 8 and 53 years. Most subjects in the two trials were 12 or older.

CONTRAINDICATIONS
1. ORAP (pimozide) is contraindicated in the treatment of simple tics or tics other than those associated with Tourette’s Disorder.

2. ORAP should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics.

3. Because ORAP prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the
electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS – Drug Interactions).

4. ORAP is contraindicated in patients with severe toxic central nervous system depression or comatose states from any cause.

5. ORAP is contraindicated in patients with hypersensitivity to it. As it is not known whether cross-sensitivity exists among the antipsychotics, pimozide should be used with appropriate caution in patients who have demonstrated hypersensitivity to other antipsychotic drugs.

6. Ventricular arrhythmias have been rarely associated with the use of macrolide antibiotics in patients with prolonged QT intervals, as might be produced by ORAP. Specifically, two sudden deaths have been reported when clarithromycin was added to ongoing pimozide therapy. Furthermore, some evidence suggests that pimozide is metabolized partly by the enzyme system cytochrome P450 3A4 (CYP 3A4). Macrolide antibiotics are inhibitors of CYP 3A4, and thus could potentially impede pimozide metabolism. For these reasons, ORAP is contraindicated in patients receiving the macrolide antibiotics clarithromycin, erythromycin, azithromycin, dirithromycin, and troleandomycin.

7. Concomitant use in patients taking Celexa or Lexapro is contraindicated (see Precautions - Drug Interactions - Pimozide and Celexa).

8. Clinical drug interaction studies have demonstrated that pimozide is also metabolized by CYP 2D6. Concomitant use of ORAP with paroxetine and other strong CYP 2D6 inhibitors is contraindicated (See PRECAUTIONS – Drug Interactions).

9. Concomitant use of pimozide in patients taking sertraline is contraindicated (See PRECAUTIONS – Drug Interactions).

Because azole antifungal agents are also inhibitors of the CYP 3A4 enzymes and thus may likewise impair pimozide metabolism, ORAP is contraindicated in patients receiving the azole antifungal agents itraconazole and ketoconazole.

Similarly, protease inhibitor drugs are also inhibitors of CYP 3A4, and thus ORAP is contraindicated in patients receiving protease inhibitors such as ritonavir, saquinovir, indinavir, and nelfinavir. (See PRECAUTIONS – Drug Interactions.)

Nefazodone is a potent inhibitor of CYP 3A4, and its concomitant use with ORAP is also contraindicated.

Other drugs that are relatively less potent inhibitors of CYP 3A4 should also be avoided, in view of the risks: e.g. zileuton, fluvoxamine.

WARNINGS
The use of ORAP (pimozide) in the treatment of Tourette’s Disorder involves different risk/benefit considerations than when antipsychotic drugs are used to treat other conditions. Consequently, a decision to use ORAP should take into consideration the following (see also PRECAUTIONS – Information for Patients).

### Tardive Dyskinesia

A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

Both the risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.

There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and, 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome.

(For further information about the description of tardive dyskinesia and its clinical detection, please refer to ADVERSE REACTIONS and PRECAUTIONS – Information for Patients.)

### Neuroleptic Malignant Syndrome (NMS)

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including
catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.

The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology.

The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.

If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.

Hyperpyrexia, not associated with the above symptom complex, has been reported with other antipsychotic drugs.

Other
Sudden, unexpected deaths have occurred in experimental studies of conditions other than Tourette’s Disorder. These deaths occurred while patients were receiving dosages in the range of 1 mg per kg. One possible mechanism for such deaths is prolongation of the QT interval predisposing patients to ventricular arrhythmia. An electrocardiogram should be performed before ORAP treatment is initiated and periodically thereafter, especially during the period of dose adjustment.

ORAP may have a tumorigenic potential. Based on studies conducted in mice, it is known that pimozide can produce a dose-related increase in pituitary tumors. The full significance of this finding is not known, but should be taken into consideration in the physician’s and patient’s decisions to use this drug product. This finding should be given special consideration when the patient is young and chronic use of pimozide is anticipated (see PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility).

PRECAUTIONS
Leukopenia, Neutropenia and Agranulocytosis
Class Effect: In clinical trial and/or postmarketing experience, events of leukopenia/neutropenia and agranulocytosis have been reported temporally related to antipsychotic agents.

Reference ID: 3020950
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ORAP should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.

Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm³) should discontinue ORAP and have their WBC followed until recovery.

General
ORAP (pimozide) may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery, especially during the first few days of therapy.

ORAP produces anticholinergic side effects and should be used with caution in individuals whose conditions may be aggravated by anticholinergic activity.

ORAP should be administered cautiously to patients with impairment of liver or kidney function, because it is metabolized by the liver and excreted by the kidneys.

Antipsychotics should be administered with caution to patients receiving anticonvulsant medication, with a history of seizures, or with EEG abnormalities, because they may lower the convulsive threshold. If indicated, adequate anticonvulsant therapy should be maintained concomitantly.

Information for Patients
Treatment with ORAP exposes the patient to serious risks. A decision to use ORAP chronically in Tourette’s Disorder is one that deserves full consideration by the patient (or patient’s family) as well as by the treating physician. Because the goal of treatment is symptomatic improvement, the patient’s view of the need for treatment and assessment of response are critical in evaluating the impact of therapy and weighing its benefits against the risks. Since the physician is the primary source of information about the use of a drug in any disease, it is recommended that the following information be discussed with patients and/or their families.

ORAP is intended only for use in patients with Tourette’s Disorder whose symptoms are severe and who cannot tolerate, or who do not respond to HALDOL® (haloperidol).

Given the likelihood that a proportion of patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.
There is limited information available on the use of ORAP in children under 12 years of age.

The information available on ORAP from foreign marketing experience and from U.S. clinical trials indicates that ORAP has a side effect profile similar to that of other antipsychotic drugs. Patients should be informed that all types of side effects associated with the use of antipsychotics may be associated with the use of ORAP.

In addition, sudden, unexpected deaths have occurred in patients taking high doses of ORAP for conditions other than Tourette’s Disorder. These deaths may have been the result of an effect of ORAP upon the heart. Therefore, patients should be instructed not to exceed the prescribed dose of ORAP and they should realize the need for the initial ECG and for follow-up ECGs during treatment.

Also, pimozide, at a dose about 15 times that given humans, caused an increase in the number of benign tumors of the pituitary gland in female mice. It is not possible to say how important this is. Similar tumors were not seen in rats given pimozide, nor at lower doses in mice, which is reassuring. However, any such finding must be considered to suggest a possible risk of long term use of the drug.

Because substances in grapefruit juice may inhibit the metabolism of pimozide by CYP 3A4, patients should be advised to avoid grapefruit juice.

**Laboratory Tests**

An ECG should be done at baseline and periodically thereafter throughout the period of dose adjustment. Any indication of prolongation of QTc interval beyond an absolute limit of 0.47 seconds (children) or 0.52 seconds (adults), or more than 25% above the patient’s original baseline should be considered a basis for stopping further dose increase (see **CONTRAINDICATIONS**) and considering a lower dose.

Since hypokalemia has been associated with ventricular arrhythmias, potassium insufficiency, secondary to diuretics, diarrhea, or other cause, should be corrected before ORAP therapy is initiated and normal potassium maintained during therapy.

**Drug Interactions**

Because ORAP prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. Accordingly, pimozide should not be given with doxetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparflaxacin, gatifloxacin, moxiflaxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects. Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Such concomitant administration should not be undertaken (see **CONTRAINDICATIONS**).
Since ORAP is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such asazole antifungal agents and protease inhibitor drugs (see CONTRAINDICATIONS).

Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C_max of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of pimozide and Celexa or Lexapro is contraindicated (See CONTRAINDICATIONS).

CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see CONTRAINDICATIONS).

As CYP 1A2 may also contribute to the metabolism of ORAP, prescribers should be aware of the theoretical potential for drug interactions with inhibitors of this enzymatic system.

ORAP may be capable of potentiating CNS depressants, including analgesics, sedatives, anxiolytics, and alcohol.

Rare case reports have suggested possible additive effects of pimozide and fluoxetine leading to bradycardia.

Concomitant administration of pimozide and sertraline should be contraindicated (See CONTRAINDICATIONS).

**Pharmacogenomics** Individuals with genetic variations resulting in poor CYP 2D6 metabolism (approximately 5 to 10% of the population) exhibit higher pimozide concentrations than extensive CYP 2D6 metabolizers. The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP 2D6 inhibitors such as paroxetine. The time to achieve steady state pimozide concentrations is expected to be longer (approximately 2 weeks) in poor CYP 2D6 metabolizers because of the prolonged half-life. Alternative dosing strategies are recommended in patients who are genetically poor CYP 2D6 metabolizers (see DOSAGE and ADMINISTRATION).

**Interaction with Food**
Patients should avoid grapefruit juice because it may inhibit the metabolism of pimozide by CYP 3A4.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**
Carcinogenicity studies were conducted in mice and rats. In mice, pimozide causes a dose-related increase in pituitary and mammary tumors.
When mice were treated for up to 18 months with pimozide, pituitary gland changes developed in females only. These changes were characterized as hyperplasia at doses approximating the human dose and adenoma at doses about fifteen times the maximum recommended human dose on a mg per kg basis. The mechanism for the induction of pituitary tumors in mice is not known.

Mammary gland tumors in female mice were also increased, but these tumors are expected in rodents treated with antipsychotic drugs which elevate prolactin levels. Chronic administration of an antipsychotic also causes elevated prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with antipsychotic drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of these drugs and mammary tumorigenesis. The available evidence, however, is considered too limited to be conclusive at this time.

In a 24-month carcinogenicity study in rats, animals received up to 50 times the maximum recommended human dose. No increased incidence of overall tumors or tumors at any site was observed in either sex. Because of the limited number of animals surviving this study, the meaning of these results is unclear.

Pimozide did not have mutagenic activity in the Ames test with four bacterial test strains, in the mouse dominant lethal test or in the micronucleus test in rats.

Reproduction studies in animals were not adequate to assess all aspects of fertility. Nevertheless, female rats administered pimozide had prolonged estrus cycles, an effect also produced by other antipsychotic drugs.

**Pregnancy**

**Category C.** Reproduction studies performed in rats and rabbits at oral doses up to 8 times the maximum human dose did not reveal evidence of teratogenicity. In the rat, however, this multiple of the human dose resulted in decreased pregnancies and in the retarded development of fetuses. These effects are thought to be due to an inhibition or delay in implantation which is also observed in rodents administered other antipsychotic drugs. In the rabbit, maternal toxicity, mortality, decreased weight gain, and embryotoxicity including increased resorptions were dose-related. Because animal reproduction studies are not always predictive of human response, pimozide should be given to a pregnant woman only if the potential benefits of treatment clearly outweigh the potential risks.

**Nonteratogenic effects.** Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These
complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

ORAP should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

**Labor and Delivery**
This drug has no recognized use in labor or delivery.

**Nursing Mothers**
It is not known whether pimozide is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity and unknown cardiovascular effects in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

**Pediatric Use**
Although Tourette's Disorder most often has its onset between the ages of 2 and 15 years, information on the use and efficacy of ORAP in patients less than 12 years of age is limited. A 24-week open label study in 36 children between the ages of 2 and 12 demonstrated that pimozide has a similar safety profile in this age group as in older patients and there were no safety findings that would preclude its use in this age group.

Because its use and safety have not been evaluated in other childhood disorders, ORAP is not recommended for use in any condition other than Tourette’s Disorder.

**ADVERSE REACTIONS**

**General**

*Extrapyramidal Reactions:* Neuromuscular (extrapyramidal) reactions during the administration of ORAP® (pimozide) have been reported frequently, often during the first few days of treatment. In most patients, these reactions involved Parkinson-like symptoms which, when first observed, were usually mild to moderately severe and usually reversible.

Other types of neuromuscular reactions (motor restlessness, dystonia, akathisia, hyperreflexia, opisthotonos, oculogyric crises) have been reported far less frequently. Severe extrapyramidal reactions have been reported to occur at relatively low doses. Generally the occurrence and severity of most extrapyramidal symptoms are dose-related since they occur at relatively high doses and have been shown to disappear or become less severe when the dose is reduced. Administration of antiparkinson drugs such as benztropine mesylate or trihexyphenidyl hydrochloride may be required for control of such reactions. It should be noted that persistent extrapyramidal reactions have been reported and that the drug may have to be discontinued in such cases.

*Withdrawal Emergent Neurological Signs:* Generally, patients receiving short term therapy experience no problems with abrupt discontinuation of antipsychotic drugs.
However, some patients on maintenance treatment experience transient dyskinetic signs after abrupt withdrawal. In certain of these cases the dyskinetic movements are indistinguishable from the syndrome described below under “Tardive Dyskinesia” except for duration. It is not known whether gradual withdrawal of antipsychotic drugs will reduce the rate of occurrence of withdrawal emergent neurological signs, but until further evidence becomes available, it seems reasonable to gradually withdraw use of ORAP.

**Tardive Dyskinesia:** ORAP may be associated with persistent dyskinesias. Tardive dyskinesia, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may appear in some patients on long-term therapy or may occur after drug therapy has been discontinued. The risk appears to be greater in elderly patients on high-dose therapy, especially females. The symptoms are persistent and in some patients appear irreversible. The syndrome is characterized by rhythmic involuntary movements of tongue, face, mouth or jaw (e.g., protrusion of tongue, puffing of cheeks, puckering of mouth, chewing movements). Sometimes these may be accompanied by involuntary movements of extremities and the trunk.

There is no known effective treatment for tardive dyskinesia; antiparkinson agents usually do not alleviate the symptoms of this syndrome. It is suggested that all antipsychotic agents be discontinued if these symptoms appear. Should it be necessary to reinstitute treatment, or increase the dosage of the agent, or switch to a different antipsychotic agent, this syndrome may be masked.

It has been reported that fine vermicular movement of the tongue may be an early sign of tardive dyskinesia and if the medication is stopped at that time the syndrome may not develop.

**Electrocardiographic Changes:** Electrocardiographic changes have been observed in clinical trials of ORAP in Tourette’s Disorder and schizophrenia. These have included prolongation of the QT interval, flattening, notching and inversion of the T wave and the appearance of U waves. Sudden, unexpected deaths and grand mal seizure have occurred at doses above 20 mg/day.

**Neuroleptic Malignant Syndrome:** Neuroleptic malignant syndrome (NMS) has been reported with ORAP. (See WARNINGS for further information concerning NMS.)

**Hyperpyrexia:** Hyperpyrexia has been reported with other antipsychotic drugs.

**Clinical Trials**
The following adverse reaction tabulation was derived from 20 patients in a 6-week long placebo-controlled clinical trial of ORAP in Tourette’s Disorder.

<table>
<thead>
<tr>
<th>Body System/ Adverse Reaction</th>
<th>Pimozide (N = 20)</th>
<th>Placebo (N = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Reference ID: 3020950
<table>
<thead>
<tr>
<th>Body as a Whole</th>
<th>1</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gastrointestinal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dry Mouth</td>
<td>5</td>
<td>1</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Vomiting</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Constipation</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Eructations</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Thirsty</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Appetite increase</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td><strong>Endocrine</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Menstrual disorder</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Breast secretions</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Musculoskeletal</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Muscle cramps</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Muscle tightness</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Stooped posture</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td><strong>CNS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drowsiness</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>Sedation</td>
<td>14</td>
<td>5</td>
</tr>
<tr>
<td>Insomnia</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Dizziness</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Akathisia</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Rigidity</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Speech disorder</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Handwriting change</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Akinesia</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td><strong>Psychiatric</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Excitement</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Nervous</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Adverse behavior effect</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td><strong>Special Senses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visual disturbance</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Taste change</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Sensitivity of eyes to light</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Decrease accommodation</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Spots before eyes</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td><strong>Urogenital</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Impotence</td>
<td>3</td>
<td>0</td>
</tr>
</tbody>
</table>
The following adverse event tabulation was derived from 36 children (age 2 to 12) in a 24-week open trial of ORAP in Tourette’s Disorder.

<table>
<thead>
<tr>
<th>Body System/Adverse Reaction</th>
<th>Number of Patients Experiencing Each Event (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Events (N=36)</td>
</tr>
</tbody>
</table>

### Body as a Whole
- Asthenia 9 (25.0) 5 (13.8)
- Headache 8 (22.2) 1 (2.7)

### Gastrointestinal
- Dysphagia 1 (2.7) 1 (2.7)
- Increased Salivation 5 (13.8) 2 (5.5)

### Musculoskeletal
- Myalgia 1 (2.7) 1 (2.7)

### Central Nervous System
- Dreaming Abnormal 1 (2.7) 1 (2.7)
- Hyperkinesia 2 (5.5) 1 (2.7)
- Somnolence 10 (27.7) 9 (25.0)
- Torticollis 1 (2.7) 1 (2.7)
- Tremor, Limbs 1 (2.7) 1 (2.7)

### Psychiatric
- Adverse Behavior Effect 10 (27.7) 8 (22.2)
- Nervous 3 (8.3) 2 (5.5)

### Skin
- Rash 3 (8.3) 1 (2.7)

### Special Senses
Because clinical investigational experience with ORAP in Tourette’s Disorder is limited, uncommon adverse reactions may not have been detected. The physician should consider that other adverse reactions associated with antipsychotics may occur.

**Other Adverse Reactions**

In addition to the adverse reactions listed above, those listed below have been reported in U.S. clinical trials of ORAP in conditions other than Tourette’s Disorder.

**Body as a Whole:** Asthenia, chest pain, periorbital edema

**Cardiovascular/Respiratory:** Postural hypotension, hypotension, hypertension, tachycardia, palpitations

**Gastrointestinal:** Increased salivation, nausea, vomiting, anorexia, GI distress

**Endocrine:** Loss of libido

**Metabolic/Nutritional:** Weight gain, weight loss

**Central Nervous System:** Dizziness, tremor, parkinsonism, fainting, dyskinesia

**Psychiatric:** Excitement

**Skin:** Rash, sweating, skin irritation

**Special Senses:** Blurred vision, cataracts

**Urogenital:** Nocturia, urinary frequency

**Postmarketing Reports**

The following experiences were described in spontaneous postmarketing reports. These reports do not provide sufficient information to establish a clear causal relationship with the use of ORAP.

**Gastrointestinal:** Gingival hyperplasia in one patient

**Hematologic:** Hemolytic anemia

**Metabolic/Nutritional:** Hyponatremia
**OVERDOSAGE**

In general, the signs and symptoms of overdosage with ORAP (pimozide) would be an exaggeration of known pharmacologic effects and adverse reactions, the most prominent of which would be: 1) electrocardiographic abnormalities, 2) severe extrapyramidal reactions, 3) hypotension, 4) a comatose state with respiratory depression.

In the event of overdosage, gastric lavage, establishment of a patent airway and, if necessary, mechanically-assisted respiration are advised. Electrocardiographic monitoring should commence immediately and continue until the ECG parameters are within the normal range. Hypotension and circulatory collapse may be counteracted by use of intravenous fluids, plasma, or concentrated albumin, and vasopressor agents such as metaraminol, phenylephrine and norepinephrine.

Epinephrine should not be used. In case of severe extrapyramidal reactions, antiparkinson medication should be administered. Because of the long half-life of pimozide, patients who take an overdose should be observed for at least 4 days. As with all drugs, the physician should consider contacting a poison control center for additional information on the treatment of overdose.

**DOSAGE AND ADMINISTRATION**

**General**

The suppression of tics by ORAP requires a slow and gradual introduction of the drug. The patient’s dose should be carefully adjusted to a point where the suppression of tics and the relief afforded is balanced against the untoward side effects of the drug.

An ECG should be done at baseline and periodically thereafter, especially during the period of dose adjustment (see **WARNINGS** and **PRECAUTIONS - Laboratory Tests**). Periodic attempts should be made to reduce the dosage of ORAP to see whether or not tics persist at the level and extent first identified. In attempts to reduce the dosage of ORAP, consideration should be given to the possibility that increases of tic intensity and frequency may represent a transient, withdrawal-related phenomenon rather than a return of disease symptoms. Specifically, one to two weeks should be allowed to elapse before one concludes that an increase in tic manifestations is a function of the underlying disease syndrome rather than a response to drug withdrawal. A gradual withdrawal is recommended in any case.

**Children**

Reliable dose response data for the effects of ORAP (pimozide) on tic manifestation in Tourette’s Disorder patients below the age of twelve are not available.

Treatment should be initiated at a dose of 0.05 mg/kg preferably taken once at bedtime. The dose may be increased every third day to a maximum of 0.2 mg/kg not to exceed 10 mg/day.
At doses above 0.05 mg/kg/day, CYP 2D6 genotyping should be performed. In poor CYP 2D6 metabolizers, ORAP doses should not exceed 0.05 mg/kg/day, and doses should not be increased earlier than 14 days (see PRECAUTIONS – Pharmacogenomics).

**Adults**

In general, treatment with ORAP should be initiated with a dose of 1 to 2 mg a day in divided doses. The dose may be increased thereafter every other day. Most patients are maintained at less than 0.2 mg/kg/day, or 10 mg/day, whichever is less. Doses greater than 0.2 mg/kg/day or 10 mg/day are not recommended.

At doses above 4 mg/day, CYP 2D6 genotyping should be performed. In poor CYP 2D6 metabolizers, ORAP doses should not exceed 4 mg/day, and doses should not be increased earlier than 14 days (see PRECAUTIONS – Pharmacogenomics).

**ANIMAL PHARMACOLOGY**

A chronic study in dogs indicated that pimozide caused gingival hyperplasia when administered for several months at about 5 times the maximum recommended human dose. This condition was reversible after withdrawal.

**HOW SUPPLIED**

ORAP® (pimozide) 1 mg tablets are white, oval, scored tablets, debossed “ORAP 1”. They are available in bottles of 100 (NDC 57844-151-01).

ORAP® (pimozide) 2 mg tablets are white, oval, scored tablets, debossed “LEMMON” on one side and “ORAP 2” on the other. They are available in bottles of 100 (NDC 57844-187-01).

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

Dispense in a tight, light-resistant container as defined in the official compendium.

Pharmacist: Dispense in child-resistant container.

Manufactured for:

GATE PHARMACEUTICALS
Div. of Teva Pharmaceuticals USA
Sellersville, PA 18960

Manufactured by:

TEVA PHARMACEUTICALS USA
Sellersville, PA 18960

Rev. R 08/2011
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 17-473/S046

OTHER REVIEW(S)
Date: September 27, 2011

DRUG/NDA: Orap (pimozide) 1 mg and 2 mg Tablets

Sponsor: (b) (4)

Indication: Suppression of motor and phonic tics on patients with Tourette’s Disorder

Supplements:

<table>
<thead>
<tr>
<th>NDA</th>
<th>Supplement</th>
<th>Dated</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>017473</td>
<td>S-045</td>
<td>9-3-10</td>
<td>AP Letter Dated 12-1-10</td>
</tr>
<tr>
<td>017473</td>
<td>S-046</td>
<td>9-15-11</td>
<td>Open</td>
</tr>
</tbody>
</table>

REVIEW

NDA 017473/S-046 submitted as a “Prior Approval” supplement

Dated: 9-15-11

Reviews: None

Recommended Action: Approval

The supplement provides for revisions to the CLINICAL PHARMACOLOGY—Metabolism and Pharmacokinetics, CONTRAINDICATIONS, PRECAUTIONS—Drug Interactions, and DOSAGE AND ADMINISTRATION sections as well as the addition of a new subsection under PRECAUTIONS entitled Pharmacogenomics.

DISCUSSION

• The Agency requested these labeling revisions in a PA supplement Request letter dated 8-17-11.

• The decision to modify labeling was based on an internal review of pharmacokinetic and safety information for pimozide as related to intrinsic defects in CYP2D6 metabolism. The Agency’s review was based on the published literature as a multiple-dose PK simulation based on single-dose data for CYP2D6 genotype groups.

CONCLUSIONS

1. The sponsor has incorporated our 8-17-11 requested revisions, verbatim.

2. There are no additional changes to labeling except those changes listed in our 8-17-11 supplement request letter when compared to the last approved labeling dated 12-1-10.
3. I recommend that this review, alone, be sufficient to approve this pending supplemental application.

\{See appended electronic signature page\}

Paul David, R.Ph., CPMS

Enclosure: Annotated labeling changes

17 pages immediately following withheld for b(4) - Draft labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

PAUL A DAVID
09/27/2011

Reference ID: 3020933
DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
APPLICATION TO MARKET A NEW DRUG, BIOLOGIC,
OR AN ANTIBIOTIC DRUG FOR HUMAN USE
(Titles 21, Code of Federal Regulations, Parts 314 & 601)

APPLICATION NUMBER

APPLICANT INFORMATION

NAME OF APPLICANT
Teva Pharmaceuticals USA

DATE OF SUBMISSION
09/15/2011

TELEPHONE NO. (Include Area Code)
(215) 203-6891

FACSIMILE (FAX) Number (Include Area Code)
(215) 619-3846

APPLICANT ADDRESS (Number, Street, City, State, Country, ZIP Code or Mail Code, and U.S. License number if previously issued)
425 Privet Road
P.O. Box 1005
Horsham, PA 19044-8005

AUTHORIZED U.S. AGENT NAME & ADDRESS (Number, Street, City, State, ZIP Code, telephone & FAX number) IF APPLICABLE
Teva Neuroscience, Inc.
425 Privet Road, PO Box 1005, Horsham, Pennsylvania 19044
Office (215) 293-6481 Fax (215) 293-6498

PRODUCT DESCRIPTION

NEW DRUG OR ANTIBIOTIC APPLICATION NUMBER, OR BIOLOGICS LICENSE APPLICATION NUMBER (If previously issued)
17-473

ESTABLISHED NAME (e.g., Proper name, USP/USAN name)
Pimozide

PROPRIETARY NAME (trade name) IF ANY
ORAP

CHEMICAL/BIOCHEMICAL (BIOLOGIC) PRODUCT NAME (If any)
2H-Benzimidazol-2-one,1-(1-[1-(4,4-biox(4-fluorophenyl)

CODE NAME (If any)

STRENGTHS
1 and 2 mg

ROUTE OF ADMINISTRATION
Oral

(PROPPOSED) INDICATION(S) FOR USE:
Pimozide is indicated for the suppression of motor and phonic tics in patients with Tourette's Disorder

APPLICATION DESCRIPTION

APPLICATION TYPE

☐ NEW DRUG APPLICATION (CDA, 21 CFR 314.50) ☑ ABBREVIATED NEW DRUG APPLICATION (ANDA, 21 CFR 314.94)
☐ BIOLOGICS LICENSE APPLICATION (BLA, 21 CFR Part 601)

IF AN ANDA, IDENTIFY THE APPROPRIATE TYPE
☐ 505 (b)(1) ☐ 505 (b)(2)

IF AN ANDA, OR 505(b)(2), IDENTIFY THE REFERENCE LISTED DRUG PRODUCT THAT IS THE BASIS FOR THE SUBMISSION

Type of Drug

Holder of Approved Application

TYPE OF SUBMISSION (check one)
☐ ORIGINAL APPLICATION ☑ AMENDMENT TO APPELLING APPLICATION ☐ RESUBMISSION
☐ PENDING SUPPLEMENT ☑ ANNUAL REPORT ☐ ESTABLISHMENT DESCRIPTION SUPPLEMENT ☑ EFFICACY SUPPLEMENT
☐ LABELING SUPPLEMENT ☑ CHEMISTRY MANUFACTURING AND CONTROLS SUPPLEMENT ☐ OTHER

IF A SUBMISSION OF PARTIAL APPLICATION, PROVIDE LETTER DATE OF AGREEMENT TO PARTIAL SUBMISSION:

IF A SUPPLEMENT, IDENTIFY THE APPROPRIATE CATEGORY
☐ CBE ☐ CBE-30 ☑ Prior Approval (PA)

REASON FOR SUBMISSION
Safety Labeling Changes

PROPOSED MARKETING STATUS (check one)
☐ PRESCRIPTION PRODUCT (Rx) ☐ OVER THE COUNTER PRODUCT (OTC)

NUMBER OF VOLUMES SUBMITTED
1

THIS APPLICATION IS
☐ PAPER ☑ PAPER AND ELECTRONIC ☐ ELECTRONIC

ESTABLISHMENT INFORMATION (Full establishment information should be provided in the body of the Application.)
Provide locations of all manufacturing, packaging and control sites for drug substance and drug product (continuation sheets may be used if necessary) include name, address, contact telephone number, registration number (CEN), DMF number, and manufacturing steps and/or type of testing (e.g. Final dosage form, Stability testing) conducted at the site. Please indicate whether the site is ready for inspection or, if not, when it will be ready.

Cross References (list related License Applications, INDs, NDAs, PMAs, 510(k)s, IDEs, BFMFs, and DMFs referenced in the current application)
CERTIFICATION

I agree to update this application with new safety information about the product that may reasonably affect the statement of contraindications, warnings, precautions, or adverse reactions in the draft labeling. I agree to submit safety update reports as provided for by regulation or as requested by FDA. If this application is approved, I agree to comply with all applicable laws and regulations that apply to approved applications, including, but not limited to the following:

1. Good manufacturing practice regulations in 21 CFR Parts 210, 211 or applicable regulations, Parts 666, and/or 820.
3. Labeling regulations in 21 CFR Parts 201, 606, 610, 660, and/or 809.
6. Regulations on Reports in 21 CFR 314.90, 314.81, 600.80, and 600.81.
7. Local, state and Federal environmental impact laws.

This application contains the following items: (Check all that apply)

1. Index
2. Labeling (check one) [ ] Draft Labeling [ ] Final Printed Labeling
3. Summary (21 CFR 314.50 (c))
4. Chemistry section
   A. Chemistry, manufacturing, and controls information (e.g., 21 CFR 314.50(d)(1); 21 CFR 601.2)
   B. Samples (21 CFR 314.50 (e)(1); 21 CFR 601.2 (a)) (Submit only upon FDA's request)
   C. Methods validation package (e.g., 21 CFR 314.50(d)(2)(i); 21 CFR 601.2)
5. Nonclinical pharmacology and toxicology section (e.g., 21 CFR 314.50(d)(2); 21 CFR 601.2)
6. Human pharmacokinetics and bioavailability section (e.g., 21 CFR 314.50(d)(3); 21 CFR 601.2)
7. Clinical Microbiology (e.g., 21 CFR 314.50(d)(4))
8. Clinical data section (e.g., 21 CFR 314.50(c)(5); 21 CFR 601.2)
9. Safety update report (e.g., 21 CFR 314.50(d)(5)(v)(b); 21 CFR 601.2)
10. Statistical section (e.g., 21 CFR 314.50(d)(6); 21 CFR 601.2)
11. Case report tabulations (e.g., 21 CFR 314.50(f)(1); 21 CFR 601.2)
12. Case report forms (e.g., 21 CFR 314.50 (f)(2); 21 CFR 601.2)
13. Patent information on any patent which claims the drug (21 U.S.C. 355(b) or (c))
14. A patent certification with respect to any patent which claims the drug (21 U.S.C. 355 (b)(2) or (j)(2)(A))
15. Establishment description (21 CFR Part 630, if applicable)
16. Debarment certification (FD&C Act 355 (k)(1))
17. Field copy certification (21 CFR 314.50 (f)(3))
18. User Fee Cover Sheet (Form FDA 3397)
19. Financial Information (21 CFR Part 54)
20. OTHER (Specify) Structured Product Labeling (SPL)

Signature of Responsible Official or Agent

Public reporting burden for this collection of information is estimated to average 24 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Central Document Room
5001-B Ammendale Road
Baltimore, MD 20705-1266

Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research (HFM-69)
1401 Rockville Pike
Rockville, MD 20852-1448

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.